Lupin names new chief corporate development officer

Lupin has announced the appointment of pharmaceutical sector veteran Theresa Stevens as its new chief corporate development officer for its global operations.

Ms Stevens joins the company from Aptalis Pharma, where she served in the equivalent role and was responsible for mergers and acquisition activities, strategy and global business development.

At Lupin, she will fulfil a similar position, driving the company's growth plans and leveraging her more than 27 years of industry experience in managing strategy, corporate development, takeovers and licensing.

In addition to her work with Aptalis, Ms Stevens previously spent nine years with Novartis, where she held several positions of increasing responsibility.

Nilesh Gupta, managing director at Lupin, said: "I am sure her rich experience in the areas of mergers and acquisitions and specialty strategy within the pharmaceutical and biotech industry sector will help Lupin's growth plans."

The company also recently confirmed a new collaboration with Japanese pharmaceutical firm Yoshindo, resulting in the creation of a joint venture called YL Biologics.